RK Smiley Research Grant Program

Dr. R. Kennedy Smiley

The RK Smiley Research Grant program provides start up grants aimed at pilot projects expected to lead to larger follow-up studies funded by CIHR or other grant funding agencies.

Established in 2011 to mark the Fortieth Anniversary of the Canadian Hematology Society’s service and to support hematology practitioners in Canada, this award is named in honour of the CHS Founding President, Dr. R. Kennedy Smiley, who was also instrumental in founding the University of Ottawa’s medical school. Many impressive submissions from across Canada have been received in response to the announcement of this new research grant program since its inception.

The annual invitation for submissions, is typically announced in late fall, the deadline is February 28th each year, and the winners announced in May.

Eligibility Criteria: Applicants may be clinicians or scientists with a project relevant to the field of hematology and must be members of the Canadian Hematology Society. Preference will be given to groups who will benefit maximally from the limited start up funds.

 

RK Smiley Research Grant Winners

2019

  • 2019

    Dr. Miriam Kimpton

    Thromboprophylaxis with apixaban in polycythemia vera and JAK2- positive essential thrombocythemia patients: A pilot randomized controlled trial assessing feasibility.

    University of Ottawa

  • 2019

    Dr. Kevin Kuo

    A multicenter study evaluating the reliability and validity of the Rowland Universal Dementia Assessment Scale (RUDAS) and predictors of RUDAS performance in adults with Sickle Cell Disease

    University of Toronto

2018

  • 2018

    Dr. Christine Cserti-Gazdewich

    The Monocyte Monolayer Assay: Enhancing Care for the Untrasfusables

    Blood Transfusion Medicine, Toronto General Hospital

  • 2018

    Dr. Robert Kridel

    Identifying new therapeutic targets for double-hit lymphoma using CRISPR-Cas screens

    Medical Oncology & Hematology Princess Margaret Cancer Centre, Toronto

2017

  • 2017

    Dr. Steven Chan

    Genome-Wide Identification of Synthetic Lethal Genes against TET2 Mutations in Acute Myeloid Leukemia (AML)

    Princess Margaret, University Health Network, Toronto

  • 2017

    Dr. Bertrand Routy

    Influence of gut microbiota on anticancer activity of immuno-therapeutic strategies in patients with multiple myeloma

    McGill University, Montreal

2016

  • 2016

    Dr. Signy Chow

    Next Generation Sequencing of circulating tumor DNA (ctDNA) for Minimal Residual Disease (MRD) and Monitoring of Clonal Evolution in Multiple Myeloma (MM).

    University Health Network, Toronto

  • 2016

    Dr. Ziad Solh

    Neonatal Outcomes after Transfusion of ABO Non-Identical Blood (Neo-ABO)

    McMaster University, Hamilton, Ontario

2015

  • 2015

    Dr. Yulia Lin

    Setting the benchmark metric for red blood cell transfusion (RBC) to allow for assessment of optimal transfusion care: A pilot quality project at 10 hospitals.

    Sunnybrook Health Sciences Centre and University Health Network, Toronto

  • 2015

    Dr. Ana Nijnik

    Genome-wide Identification of p53-Regulated Genes in Hematopoietic Stem and Progenitor Cells

    McMaster University, Hamilton, Ontario

2014

  • 2014

    Dr. Geerte van Sluis

    A Pilot Study Investigating the Significance of Novel Factor Xa Inhibitor Interactions with Dexamethasone-Containing Regimens for Multiple Myeloma

    University of British Columbia

  • 2014

    Dr. Paul Spagnuolo

    Mitophagy in the development of leukemia stem cell mitochondrial phenotype

    University Waterloo, School of Pharmacy

2013

  • 2013

    Dr. Brent Williams

    Treatment of AML xenografted mice with CD16+NK-92 and anti-CD123 antibody

    Princess Margaret Hospital, Toronto

  • 2013

    Dr. Isaac Odame

    White matter integrity and neurocognition in sickle cell patients

    University of Toronto

  • 2013

    Dr. Nathalie A. Johnson

    The role of FAZ mutations in chemotherapy-resistant lymphomas

    McGill University, Montreal

2012

  • 2012

    Dr. Hubert Tsui

    “Sensing” Hematopoiesis

    University of Toronto

  • 2012

    Dr. Christian Steidl

    Prognostic markers in relapsed Hodgkin lymphoma

    BC Cancer Centre

  • 2012

    Dr. Michael Rauh

    Myeloid-derived suppressor cells as potential novel mediators of Factor VIII tolerance in Hemophilia A

    Queen’s University, Kingston, Ontario